A Phase II study of the efficacy and safety of Perflubutane for predicting highly Tumor Infiltrating Lymphocytes in early breast cancer (AppTIL study)
Phase 2
Recruiting
- Conditions
- Early Breast Cancer (cStage I-IIIA)
- Registration Number
- JPRN-UMIN000050067
- Lead Sponsor
- Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients undergoing preoperative treatment for breast cancer 2. Patients with a history of breast cancer on the affected side 3. Patients with a history of hypersensitivity to perflubutane 4. Patients with allergy to eggs or egg products 5. Patients with arteriovenous shunts in the heart or lungs 6. Patients with serious cardiac or pulmonary disease 7. Patients deemed inappropriate by the principal investigator or subinvestigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method